Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants

Journal of Virology

Volumn 91, Issue 24, 2017, Pages

  Wong, Terianne M ^a   Allen, James D ^a   Bebin Blackwell, Anne Gaelle ^a   Carter, Donald M ^a   Alefantis, Timothy ^b   DiNapoli, Joshua ^b   Kleanthous, Harold ^b   Ross, Ted M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

COBRA; H3N2; Hemagglutination inhibition; Influenza; Mice

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA A (H3N2); MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; WILD TYPE; ANIMAL; BLOOD; CHEMISTRY; CLASSIFICATION; COMPUTER AIDED DESIGN; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H3N2); MUSTELA PUTORIUS FURO; ORTHOMYXOVIRUS INFECTION; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; COMPUTER-AIDED DESIGN; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 85035748792     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01581-17     Document Type: Article

References (46)

1. Monto AS. 2010. Seasonal influenza and vaccination coverage. Vaccine 28(Suppl 4):D33-D44. https://doi.org/10.1016/j.vaccine.2010.08.027
2. Ellebedy AH, Webby RJ. 2009. Influenza vaccines. Vaccine 27(Suppl 4):D65-D68. https://doi.org/10.1016/j.vaccine.2009.08.038
3. Epperson S, Jhung M, Richards S, Quinlisk P, Ball L, Moll M, Boulton R, Haddy L, Biggerstaff M, Brammer L, Trock S, Burns E, Gomez T, Wong KK, Katz J, Lindstrom S, Klimov A, Bresee JS, Jernigan DB, Cox N, Finelli L. 2013. Human infections with influenza A(H3N2) variant virus in the United States, 2011-2012. Clin Infect Dis 57(Suppl 1):S4-S11. https://doi.org/10.1093/cid/cit272
4. Huang JW, Yang JM. 2011. Changed epitopes drive the antigenic drift for influenza A (H3N2) viruses. BMC Bioinformatics 12(Suppl 1):S31. https://doi.org/10.1186/1471-2105-12-S1-S31
5. Xiao Y, Moghadas SM. 2013. Impact of viral drift on vaccination dynamics and patterns of seasonal influenza. BMC Infect Dis 13:589. https://doi.org/10.1186/1471-2334-13-589
6. Anonymous. 2015. CDC presents updated estimates of flu vaccine effectiveness for the 2014-2015 season. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/news/updated-vaccine-effectiveness-2014-15.htm
7. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK, Marshfield Influenza Study Group. 2009. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 199:159-167. https://doi.org/10.1086/595861
8. Centers for Disease Control and Prevention. 2005. Seasonal influenza vaccine effectiveness. Centers for Disease Control and Prevention, Atlanta, GA
9. Du X, Dong L, Lan Y, Peng Y, Wu A, Zhang Y, Huang W, Wang D, Wang M, Guo Y. 2012. Mapping of H3N2 influenza antigenic evolution in China reveals a strategy for vaccine strain recommendation. Nat Commun 3:709. https://doi.org/10.1038/ncomms1710
10. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305:371-376. https://doi.org/10.1126/science.1097211
11. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, Christodoulou E, Walker PA, Liu J, Skehel JJ, Gamblin SJ, Hay AJ, Daniels RS, McCauley JW. 2012. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci USA 109: 21474-21479. https://doi.org/10.1073/pnas.1218841110
12. Crevar CJ, Ross TM. 2008. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 5:131. https://doi.org/10.1186/1743-422X-5-131
13. Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM. 2012. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol 19:128-139. https://doi.org/10.1128/CVI.05533-11
14. Giles BM, Crevar CJ, Carter DM, Bissel SJ, Schultz-Cherry S, Wiley CA, Ross TM. 2012. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205:1562-1570. https://doi.org/10.1093/infdis/jis232
15. Giles BM, Ross TM. 2011. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29:3043-3054. https://doi.org/10.1016/j.vaccine.2011.01.100
16. Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortes-Garcia G, Vogel TU, Parrington M, Kleanthous H, Ross TM. 2016. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol 90:4720-4734. https://doi.org/10.1128/JVI.03152-15
17. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. 2009. The SWISSMODEL Repository and associated resources. Nucleic Acids Res 37: D387-D392. https://doi.org/10.1093/nar/gkn750
18. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201. https://doi.org/10.1093/bioinformatics/bti770
19. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Gallo Cassarino T, Bertoni M, Bordoli L, Schwede T. 2014. SWISSMODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 42:W252-W258. https://doi.org/10.1093/nar/gku340
20. DeLano WL. 2002. The PyMOL molecular graphics system: MacPyMOL v1.7.6.2. DeLano Scientific, San Carlos, CA
21. Lewis NS, Anderson TK, Kitikoon P, Skepner E, Burke DF, Vincent AL. 2014. Substitutions near the hemagglutinin receptor-binding site determine the antigenic evolution of influenza A H3N2 viruses in U.S. swine. J Virol 88:4752-4763. https://doi.org/10.1128/JVI.03805-13
22. Stray SJ, Pittman LB. 2012. Subtype-and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin. Virol J 9:91. https://doi.org/10.1186/1743-422X-9-91
23. Arevalo MT, Wong TM, Ross T. 2 June 2016. Expression and purification of virus-like particles for vaccination. J Vis Exp 112:e54041. https://doi.org/10.3791/54041
24. Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. 2014. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol 88:13580-13592. https://doi.org/10.1128/JVI.02289-14
25. Jang YH, Seong BL. 2014. Options and obstacles for designing a universal influenza vaccine. Viruses 6:3159-3180. https://doi.org/10.3390/v6083159
26. Zhang H, Wang L, Compans RW, Wang BZ. 2014. Universal influenza vaccines, a dream to be realized soon. Viruses 6:1974-1991. https://doi.org/10.3390/v6051974
27. Carter DM, Bloom CE, Nascimento EJ, Marques ET, Craigo JK, Cherry JL, Lipman DJ, Ross TM. 2013. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J Virol 87:1400-1410. https://doi.org/10.1128/JVI.02257-12
28. Kirchenbaum GA, Ross TM. 2014. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol 28:71-76. https://doi.org/10.1016/j.coi.2014.02.005
29. Tsang TK, Cauchemez S, Perera RA, Freeman G, Fang VJ, Ip DK, Leung GM, Malik Peiris JS, Cowling BJ. 2014. Association between antibody titers and protection against influenza virus infection within households. J Infect Dis 210:684-692. https://doi.org/10.1093/infdis/jiu186
30. Corti D, Suguitan AL, Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Investig 120:1663-1673. https://doi.org/10.1172/JCI41902
31. Hensley SE, Das SR, Bailey AL, Schmidt LM, Hickman HD, Jayaraman A, Viswanathan K, Raman R, Sasisekharan R, Bennink JR, Yewdell JW. 2009. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326:734-736. https://doi.org/10.1126/science.1178258
32. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86:5774-5781. https://doi.org/10.1128/JVI.00137-12
33. Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, Garcia-Sastre A, Albrecht RA. 2014. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88:3432-3442. https://doi.org/10.1128/JVI.03004-13
34. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, Garcia-Sastre A, Palese P. 2013. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87:10435-10446. https://doi.org/10.1128/JVI.01715-13
35. Ross TM, Xu Y, Bright RA, Robinson HL. 2000. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1:127-131. https://doi.org/10.1038/77802
36. Green TD, Montefiori DC, Ross TM. 2003. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77:2046-2055. https://doi.org/10.1128/JVI.77.3.2046-2055.2003
37. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S. 2004. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4:1633-1649. https://doi.org/10.1002/pmic.200300771
38. Huang ZZ, Yu L, Huang P, Liang LJ, Guo Q. 2017. Charged amino acid variability related to N-glycosylation and epitopes in A/H3N2 influenza: hemagglutinin and neuraminidase. PLoS One 12:e0178231. https://doi.org/10.1371/journal.pone.0178231
39. WHO Global Influenza Surveillance Network. 2011. Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization, Geneva, Switzerland
40. Katz JM, Hancock K, Xu X. 2011. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 9:669-683. https://doi.org/10.1586/eri.11.51
41. Oh DY, Barr IG, Mosse JA, Laurie KL. 2008. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 46:2189-2194. https://doi.org/10.1128/JCM.00398-08
42. European Medicines Agency. 2014. Guideline on influenza vaccines: non-clinical and clinical module (draft). European Medicines Agency, London, United Kingdom
43. Matrosovich M, Matrosovich T, Garten W, Klenk HD. 2006. New lowviscosity overlay medium for viral plaque assays. Virol J 3:63. https://doi.org/10.1186/1743-422X-3-63
44. Sullivan K, Kloess J, Qian C, Bell D, Hay A, Lin YP, Gu Y. 2012. High throughput virus plaque quantitation using a flatbed scanner. J Virol Methods 179:81-89. https://doi.org/10.1016/j.jviromet.2011.10.003
45. Walls HH, Harmon MW, Slagle JJ, Stocksdale C, Kendal AP. 1986. Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses. J Clin Microbiol 23:240-245
46. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, Lescot M, Claverie JM, Gascuel O. 2008. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 36:W465-W469. https://doi.org/10.1093/nar/gkn180